Importance Of Process Safety In Fluid Management Of ADCs

By Mike Marciniak, Senior Director, Business Development US

Antibody-Drug Conjugates (ADCs) are a relatively new class of biopharmaceuticals. They combine the remarkable specificity of mAbs and the high potency of small molecule cytotoxins (cell killing agents). In fact, the used cytotoxins are so potent that their toxicity makes them almost useless on their own due to severe side effects. The key feature of ADCs is the sparing of healthy cells through selective delivery of the toxic substance into cancer tissue, where they cause cell death.

Vaccines and Cell and Gene Therapies (CGT) are related to ADCs in the sense that they are biopharmaceuticals as well and are generally manufactured by biotechnological processes. The vast majority of today’s ADCs are approved or developed for treating various hideous oncologic diseases, i.e. especially hard-to-treat cancers.

Learn more about the application of ADC's, and what tools allow the handling of manufacturing intermediates and finished products in closed systems without exposing them to the environment.